Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis Workshop Summary (2013) / Chapter Skim
Currently Skimming:
Appendix B: Participant Biographies
Appendix B: Participant Biographies
Pages 129-148
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 129... ...
and Julius H Jacobson Professor of Public Health, Department of Immunology and Infectious Diseases, Harvard School of Public Health (HSPH)
|
From page 130... ...
She is the former Vice President of Infectious Diseases Drug Discovery and Clinical Development of Eli Lilly, where she led the programs of a hepatitis C protease inhibitor from the discovery phase to clinical candidate (the compound is now in Phase III clinical trials) and the development of a new antibiotic from clinical development to product decision.
|
From page 131... ...
Dr. Cassell has received national and international awards for her research in infectious diseases, including two honorary degrees; the CDC Honor Award in Public Health for exceptional leadership and contributions in the development and implementation of the CDC's Emerging Infectious Disease Plan 1997; a Citation from the FDA Commissioner for her role as Chair of the review of science and technology at FDA and the report FDA: Science and Mission at Risk in 2008; and the Emmy Klineberger-Nobel Award in 2008 by the International Organization for Mycoplasmology for outstanding and sustained research contributions to the field of mycoplasmology.
|
From page 132... ...
His role is to provide strategic regulatory oversight for on-time development and registration of foundation health technologies, including vaccines, drugs, diagnostics, and public health pesticide products. His background is in biopharmaceutical global health R&D, including Clinical Development, Medical Affairs, Regulatory Affairs, and Product Safety and Pharmacovigilance.
|
From page 133... ...
Between 2008 and 2012, he was a member of the Executive Management Team of the Global Fund in Switzerland as the Director of the Strategy, Performance, and Evaluation Cluster. He is Chair of the Stop TB Partnership Coordinating Board.
|
From page 134... ...
Gordon Comstock, M.B.A., serves as the Director, Global Supply Chain, for the Partnership for Supply Chain Management, Inc. He directs the global supply chain activities supporting both the PEPFAR/USAID SCMS project and the Global Fund's Voluntary Pooled Procurement initiative.
|
From page 135... ...
As vice president of MAP International, his managerial experience includes leading international health education and pharmaceutical distribution programs with operations in the United States, Europe, Africa, Caribbean, and South America.
|
From page 136... ...
Fraser is a co-founder of the OpenMRS collaborative, a broad international collaboration to develop a flexible, open-source medical record system platform for use in developing countries. He also cofounded a training program in Rwanda to train local computer scientists to build medical information systems like OpenMRS, and co-leads a course at Harvard and MIT on the role of information systems in improving quality of care in developing countries.
|
From page 137... ...
Jose Gomez-Marquez is Director, and Principal Medical Device Designer, Little Devices Lab, MIT, and creator of MIT's first course on affordable medical device hardware, D-Lab Health. He is co-inventor of the MEDIKit platform, a series of design building blocks that empower doctors and nurses in developing countries to invent their own medical technologies.
|
From page 138... ...
Mr. Gray is a Fellow and Honorary Life Member of the Pharmaceutical Society of South Africa, a past President of the South African Association of Hospital and Institutional Pharmacists, a past President of the Hospital Pharmacy Section, and currently Chair of the Board of Pharmaceutical Practice of the International Pharmaceutical Federation.
|
From page 139... ...
Dr. Keravec has 20 years of experience as a public health consultant and project manager in Latin America, Africa, and Europe for the United Nations Development Programme; United Nations Educational, Scientific and Cultural Organization; MSH; French Ministry of Foreign Affairs; Pan American Health Organization; and Brazilian Ministry of Health.
|
From page 140... ...
, where he managed reorganization of all aspects of the national drug reference laboratory. His areas of technical expertise include pharmaceutical management of product QA and international quality standards for medicine quality testing laboratories, selection of essential medicines for standardized TB treatment, improved policy and regulatory environment for essential medicines, and improved product management information systems.
|
From page 141... ...
on translational and operational research and on delivery issues relevant to the uptake of existing and new technologies. He has been a member of the Technical Review Panel of the Global Fund for 3 years and also serves on the coordinating board of the Stop TB Partnership.
|
From page 142... ...
Since 2005, his activities have been concentrated on challenges affecting supply of QA medicines in low-resource countries, as well as access to treatment and innovation for neglected infectious diseases such as TB. Since joining The Union, his activities have also involved non-communicable diseases, such as asthma and diabetes.
|
From page 143... ...
He has a bachelor's degree in Chemical Engineering from the University of Edinburgh and a master's in Biochemical Engineering from University College London. He has been with Eli Lilly for 25 years since joining the company's Liverpool facility as a Technical Services Associate.
|
From page 144... ...
She has served on the program committees for Doctors of the World USA, Treatment Action Groups' TB/HIV project, and the Open Society Institute's Public Health Watch program, as well as on the boards of the Stop TB Partnership, European Observatory for Health Care Reform, AIDS Foundation East/West, Open Health Institute in Moscow, and International Gay and Lesbian Human Rights Commission. Robert Sebbag, M.D., is currently Vice President, Access to Medicines at Sanofi.
|
From page 145... ...
Eli Lilly's corporate responsibility vision for global health programs is to "catalyze sustainable access to improved health care outcomes for underserved populations." Mr. Sims oversees staff who are deployed globally in support of the global health strategy.
|
From page 146... ...
He has more than 18 years of global TB and essential medicines project management experience in regions including Europe, Asia, and Africa. He oversees the SIAPS core TB portfolio of activities, including collaborative efforts with WHO, the Global Fund, GDF, GLC, Stop TB partners, and field programs aimed at strengthening pharmaceutical management systems for TB control programs.
|
From page 147... ...
APPENDIX B 147 of pharmaceutical management tools and use of tools developed by MSH; management information systems; monitoring and evaluation; and development of training courses and capacity building programs. He holds a master's degree in Training and has completed Fellowships in Psychology.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.